Drugs / BR3006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06890299 | Dec 2024 → Jan 2025 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06890286 | Dec 2024 → Jan 2025 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR3006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06890286 ↗ |
| Route | Oral | “single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C” NCT06890286 ↗ |